AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

But with its cell therapy unit stalling and antibody-drug conjugate Trodelvy facing challenges, the company’s oncology ambitions were brought back under the spotlight during its third-quarter ...

Last year, Gilead reported what it said were promising topline results from the EVOKE-02 study of Trodelvy in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and chemo in patients ...

In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK.

Get the full experience! Unlock access to all videos with the Unlimited Trains.com Membership.